Heart failure & cardiomyopathiesCohort study

Epidemiology of Hypertrophic Cardiomyopathy in the United States From 2016 to 2023

JACC AdvPublished

  • observational study
  • patient-level administrative claims

Authors' conclusion

In this administrative claims-based study, the prevalence of HCM from 2016 to 2023 was 1/327 individuals, which translates to an estimated 832,956 HCM cases in the United States.

Study context

Population
Patients with ≥1 hypertrophic cardiomyopathy (HCM) diagnosis code in administrative claims from the Symphony Integrated Dataverse, United States, 2016 to 2023HCM cases in the total population of 141,003,247 patients
Participants
431,457 patients
Exposure
Nonobstructive HCM (nHCM) vs obstructive HCM (oHCM) vs symptomatic HCM

Main finding

As reported in the abstract

Prevalence of HCM · 2016-2023

prevalence rate

1/327 individuals (95% CI: 1/326-328)

Observational data: associations, not effects.

Further findings

OutcomenHCMoHCMsymptomatic HCM
Rates in nHCM and oHCM188/100,000 (95% CI: 187-189/100,000)117/100,000 (95% CI: 117-118/100,000)Not reported in the abstract
Incidence in asymptomatic and symptomatic HCMNot reported in the abstractNot reported in the abstract135/100,000 (95% CI: 134-135/100,000)
  • Incidence in asymptomatic and symptomatic HCM: asymptomatic HCM 171/100,000 (95% CI: 171-172/100,000)
  • Prevalence by age and sex: males 341/100,000 [95% CI: 339-342/100,000]
  • Prevalence by age and sex: females 277/100,000 [95% CI: 275-278/100,000]

Incidence of HCM · 2017 and 2023

2017
50/100,000 (95% CI: 50-51/100,000)
2023
56/100,000 (95% CI: 56-57/100,000)

Prevalence by age and sex

Prevalence generally increased with age

Regional distribution

Highest HCM, oHCM, and nHCM rates in the Northeast and Midwest

Original publication

Epidemiology of Hypertrophic Cardiomyopathy in the United States From 2016 to 2023. JACC Adv. Published 21 January 2026. doi:10.1016/j.jacadv.2025.102552

Summarised from the published abstract; every number is checked against it